Compare Stocks

3 / 10
Try these comparisons:

Stock Comparison

DVAX vs NVAX vs SIGA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DVAX
Dynavax Technologies Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.82B
5Y Perf.+153.3%
NVAX
Novavax, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.50B
5Y Perf.-80.8%
SIGA
SIGA Technologies, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$339M
5Y Perf.+11.9%

DVAX vs NVAX vs SIGA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DVAX logoDVAX
NVAX logoNVAX
SIGA logoSIGA
IndustryDrug Manufacturers - Specialty & GenericBiotechnologyDrug Manufacturers - Specialty & Generic
Market Cap$1.82B$1.50B$339M
Revenue (TTM)$331M$596M$94M
Net Income (TTM)$-43M$-88M$-4.04T
Gross Margin83.2%84.6%61.8%
Operating Margin3.2%-11.2%27.7%
Forward P/E31.6x3.6x2.8x
Total Debt$254M$249M$595K
Cash & Equiv.$96M$241M$155M

DVAX vs NVAX vs SIGALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DVAX
NVAX
SIGA
StockMay 20Feb 26Return
Dynavax Technologie… (DVAX)100253.3+153.3%
Novavax, Inc. (NVAX)10019.2-80.8%
SIGA Technologies, … (SIGA)100111.9+11.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: DVAX vs NVAX vs SIGA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DVAX leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. SIGA Technologies, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
DVAX
Dynavax Technologies Corporation
The Defensive Pick

DVAX carries the broadest edge in this set and is the clearest fit for defensive.

  • Beta 0.75, current ratio 10.80x
  • -13.1% margin vs SIGA's -43K%
  • Beta 0.75 vs NVAX's 2.11
Best for: defensive
NVAX
Novavax, Inc.
The Growth Play

NVAX is the clearest fit if your priority is growth exposure.

  • Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
  • 64.7% revenue growth vs SIGA's -31.8%
Best for: growth exposure
SIGA
SIGA Technologies, Inc.
The Income Pick

SIGA is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 4 yrs, beta 1.15, yield 12.7%
  • 7.6% 10Y total return vs DVAX's 2.9%
  • Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNVAX logoNVAX64.7% revenue growth vs SIGA's -31.8%
ValueSIGA logoSIGALower P/E (2.8x vs 3.6x)
Quality / MarginsDVAX logoDVAX-13.1% margin vs SIGA's -43K%
Stability / SafetyDVAX logoDVAXBeta 0.75 vs NVAX's 2.11
DividendsSIGA logoSIGA12.7% yield; 4-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)DVAX logoDVAX+59.5% vs SIGA's +1.5%
Efficiency (ROA)DVAX logoDVAX-4.6% ROA vs NVAX's -7.4%

DVAX vs NVAX vs SIGA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DVAXDynavax Technologies Corporation
FY 2024
H E P L I S A V B
96.8%$268M
Other Revenue
3.2%$9M
NVAXNovavax, Inc.
FY 2025
Product
50.0%$685M
Nuvaxovid Sales
45.6%$625M
Supply Sales
4.4%$60M
SIGASIGA Technologies, Inc.
FY 2025
Product Sales and Supportive Services
93.1%$88M
Research and Development
6.9%$7M

DVAX vs NVAX vs SIGA — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDVAXLAGGINGNVAX

Income & Cash Flow (Last 12 Months)

DVAX leads this category, winning 3 of 6 comparable metrics.

NVAX is the larger business by revenue, generating $596M annually — 6.4x SIGA's $94M. DVAX is the more profitable business, keeping -13.1% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, DVAX holds the edge at +17.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDVAX logoDVAXDynavax Technolog…NVAX logoNVAXNovavax, Inc.SIGA logoSIGASIGA Technologies…
RevenueTrailing 12 months$331M$596M$94M
EBITDAEarnings before interest/tax$19M-$47M$26M
Net IncomeAfter-tax profit-$43M-$88M-$4.04T
Free Cash FlowCash after capex$81M-$96M$33M
Gross MarginGross profit ÷ Revenue+83.2%+84.6%+61.8%
Operating MarginEBIT ÷ Revenue+3.2%-11.2%+27.7%
Net MarginNet income ÷ Revenue-13.1%-14.7%-43117.4%
FCF MarginFCF ÷ Revenue+24.4%-16.1%+35.2%
Rev. Growth (YoY)Latest quarter vs prior year+17.7%-79.1%-11.3%
EPS Growth (YoY)Latest quarter vs prior year+90.9%-102.0%
DVAX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — NVAX and SIGA each lead in 3 of 6 comparable metrics.

At 3.6x trailing earnings, NVAX trades at a 95% valuation discount to DVAX's 77.5x P/E. On an enterprise value basis, NVAX's 2.6x EV/EBITDA is more attractive than DVAX's 503.2x.

MetricDVAX logoDVAXDynavax Technolog…NVAX logoNVAXNovavax, Inc.SIGA logoSIGASIGA Technologies…
Market CapShares × price$1.8B$1.5B$339M
Enterprise ValueMkt cap + debt − cash$2.0B$1.5B$185M
Trailing P/EPrice ÷ TTM EPS77.50x3.63x14.33x
Forward P/EPrice ÷ next-FY EPS est.31.59x2.78x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple503.23x2.56x7.60x
Price / SalesMarket cap ÷ Revenue6.56x1.34x3.58x
Price / BookPrice ÷ Book value/share3.46x1.70x
Price / FCFMarket cap ÷ FCF30.24x6.96x
Evenly matched — NVAX and SIGA each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

SIGA leads this category, winning 4 of 9 comparable metrics.

DVAX delivers a -8.1% return on equity — every $100 of shareholder capital generates $-8 in annual profit, vs $-11 for SIGA. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DVAX's 0.43x. On the Piotroski fundamental quality scale (0–9), DVAX scores 6/9 vs SIGA's 5/9, reflecting solid financial health.

MetricDVAX logoDVAXDynavax Technolog…NVAX logoNVAXNovavax, Inc.SIGA logoSIGASIGA Technologies…
ROE (TTM)Return on equity-8.1%-10.7%
ROA (TTM)Return on assets-4.6%-7.4%-7.4%
ROICReturn on invested capital-0.4%+33.7%
ROCEReturn on capital employed-0.4%+100.4%+11.3%
Piotroski ScoreFundamental quality 0–9655
Debt / EquityFinancial leverage0.43x0.00x
Net DebtTotal debt minus cash$159M$8M-$154M
Cash & Equiv.Liquid assets$96M$241M$155M
Total DebtShort + long-term debt$254M$249M$595,169
Interest CoverageEBIT ÷ Interest expense-5.28x-5.10x
SIGA leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DVAX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in DVAX five years ago would be worth $15,800 today (with dividends reinvested), compared to $524 for NVAX. Over the past 12 months, DVAX leads with a +59.5% total return vs SIGA's +1.5%. The 3-year compound annual growth rate (CAGR) favors DVAX at 12.4% vs SIGA's 6.9% — a key indicator of consistent wealth creation.

MetricDVAX logoDVAXDynavax Technolog…NVAX logoNVAXNovavax, Inc.SIGA logoSIGASIGA Technologies…
YTD ReturnYear-to-date+0.8%+29.5%-15.0%
1-Year ReturnPast 12 months+59.5%+55.1%+1.5%
3-Year ReturnCumulative with dividends+42.1%+23.9%+22.2%
5-Year ReturnCumulative with dividends+58.0%-94.8%+1.4%
10-Year ReturnCumulative with dividends+2.9%-90.4%+764.0%
CAGR (3Y)Annualised 3-year return+12.4%+7.4%+6.9%
DVAX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

DVAX leads this category, winning 2 of 2 comparable metrics.

DVAX is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than NVAX's 2.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DVAX currently trades 98.5% from its 52-week high vs SIGA's 49.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDVAX logoDVAXDynavax Technolog…NVAX logoNVAXNovavax, Inc.SIGA logoSIGASIGA Technologies…
Beta (5Y)Sensitivity to S&P 5000.75x2.11x1.15x
52-Week HighHighest price in past year$15.73$11.97$9.62
52-Week LowLowest price in past year$9.20$5.80$4.29
% of 52W HighCurrent price vs 52-week peak+98.5%+77.1%+49.2%
RSI (14)Momentum oscillator 0–10075.764.447.0
Avg Volume (50D)Average daily shares traded5.7M4.4M688K
DVAX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

SIGA leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DVAX as "Buy", NVAX as "Buy", SIGA as "Buy". Consensus price targets imply 95.0% upside for NVAX (target: $18) vs 74.2% for DVAX (target: $27). SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.

MetricDVAX logoDVAXDynavax Technolog…NVAX logoNVAXNovavax, Inc.SIGA logoSIGASIGA Technologies…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$27.00$18.00
# AnalystsCovering analysts11231
Dividend YieldAnnual dividend ÷ price+12.7%
Dividend StreakConsecutive years of raises14
Dividend / ShareAnnual DPS$0.60
Buyback YieldShare repurchases ÷ mkt cap+5.5%+0.3%0.0%
SIGA leads this category, winning 1 of 1 comparable metric.
Key Takeaway

DVAX leads in 3 of 6 categories (Income & Cash Flow, Total Returns). SIGA leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.

Best OverallDynavax Technologies Corpor… (DVAX)Leads 3 of 6 categories
Loading custom metrics...

DVAX vs NVAX vs SIGA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DVAX or NVAX or SIGA a better buy right now?

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Dynavax Technologies Corporation (DVAX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DVAX or NVAX or SIGA?

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Dynavax Technologies Corporation at 77. 5x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — DVAX or NVAX or SIGA?

Over the past 5 years, Dynavax Technologies Corporation (DVAX) delivered a total return of +58.

0%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DVAX or NVAX or SIGA?

By beta (market sensitivity over 5 years), Dynavax Technologies Corporation (DVAX) is the lower-risk stock at 0.

75β versus Novavax, Inc. 's 2. 11β — meaning NVAX is approximately 182% more volatile than DVAX relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 43% for Dynavax Technologies Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — DVAX or NVAX or SIGA?

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Dynavax Technologies Corporation grew EPS 503. 2% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, SIGA leads at -5. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DVAX or NVAX or SIGA?

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus 9. 9% for Dynavax Technologies Corporation — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -1. 5% for DVAX. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DVAX or NVAX or SIGA more undervalued right now?

On forward earnings alone, SIGA Technologies, Inc.

(SIGA) trades at 2. 8x forward P/E versus 31. 6x for Dynavax Technologies Corporation — 28. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVAX: 95. 0% to $18. 00.

08

Which pays a better dividend — DVAX or NVAX or SIGA?

In this comparison, SIGA (12.

7% yield) pays a dividend. DVAX, NVAX do not pay a meaningful dividend and should not be held primarily for income.

09

Is DVAX or NVAX or SIGA better for a retirement portfolio?

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DVAX and NVAX and SIGA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DVAX is a small-cap high-growth stock; NVAX is a small-cap high-growth stock; SIGA is a small-cap deep-value stock. SIGA pays a dividend while DVAX, NVAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DVAX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Gross Margin > 49%
Run This Screen
Stocks Like

NVAX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 50%
Run This Screen
Stocks Like

SIGA

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 37%
  • Dividend Yield > 5.0%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DVAX and NVAX and SIGA on the metrics below

Revenue Growth>
%
(DVAX: 17.7% · NVAX: -79.1%)
P/E Ratio<
x
(DVAX: 77.5x · NVAX: 3.6x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.